Photodynamic therapy (PDT) holds great promise in treating veterinary and human dermatological neoplasms, including equine sarcoids, but is currently hindered by the amount of photosensitiser and light that can be delivered to lesions thicker than around 2 mm, and by the intrinsic antioxidant defences of tumour cells. We have developed a new PDT technique that combines an efficient transdermal penetration enhancer solution, for topical delivery of 5-aminolevulinic acid (ALA) photosensitiser, with acute topical post-PDT application of the glycolysis inhibitor lonidamine. We show that the new PDT combination treatment selectively kills sarcoid cells in vitro, with repeated rounds of treatment increasing sarcoid sensitisation to PDT. In vivo, ALA PDT followed by 600 μM lonidamine substantially improves treatment outcomes for occult, verrucous, nodular and fibroblastic sarcoids after 1 month (93% treatment response in 27 sarcoids), compared with PDT using only ALA (14% treatment response in 7 sarcoids).
| INTRODUCTION
Photodynamic therapy (PDT) is an evolving, cost-effective and easy to administer non-surgical treatment for a variety of dermatological cancers and pre-cancers in humans. 1, 2 PDT combines photosensitiser dyes and targeted illumination to generate cytotoxic reactive oxygen species (ROS) within the tumour. In addition to directly acting on tumour cells, PDT damages and restricts tumour microvasculature, and causes local inflammation that stimulates an immune response against the tumour. 3 Unlike surgery, because the surrounding extracellular matrix is unaffected, tissue healing and cosmesis is excellent following PDT, making it popular for cancers of the head and neck. 1, 2 Among the most popular photosensitizers is the pro-drug 5-aminolevulinic acid (ALA), which is administered either topically or orally and is licensed for use in human cancer treatments. 1, 2 ALA is a naturally occurring precursor for the biosynthesis of heme. ALA enters into all cells, although uptake is potentiated by transporters of beta-amino acids and GABA, 4 highly expressed on some cancer cells and neurons. 5, 6 ALA is then metabolized to the red-fluorescent photosensitiser protoporphyrin IX (ppIX) and finally to nonfluorescent heme. This final step relies on ferrochelatase to add Fe 2+ to ppIX and this rate-limiting enzyme is often deficient in cancer cells. 7 Thus, in the presence of excess ALA, cancer cells that combine high ALA uptake with low ppIX destruction will accumulate ppIX photosensitiser. In veterinary practice, topically applied ALA PDT has been used successfully to treat cancers of the feline nasal planum 8 and as a monotherapy or post-surgical adjunctive therapy to treat equine sarcoids. 9, 10 Sarcoids are non-metastatic but locally aggressive cutaneous fibroblastic tumours; the most common neoplasia diagnosed in horses (35%-90% of skin tumours) and noted for a high tendency for local recurrence. [11] [12] [13] They are most likely caused by bovine papillomaviruses 1 and 2. 14 Equine sarcoids can be grouped into 6 broad categories. Mild: (1) occult and (2) verrucous forms; more severe: cisplatin, and topical chemotherapy. 9, 10, 13, [15] [16] [17] [18] Each treatment has its benefits and drawbacks, such as treatment cost, availability, cosmesis, and the type and size of the lesion that can be treated. Currently, surgical excision with an adjunctive therapy gives the best long-term prognosis. For instance, CO 2 laser excision with adjunctive PDT was reported to achieve a 93% 1-year disease-free rate. 10 However, excision is only suitable for relatively small sarcoids, whilst PDT can be used to treat larger areas. An important caveat is that glycolysis inhibition must be given after ALA-PDT, because if it is given simultaneously the inhibitors prevent the metabolism of ALA to ppIX photosensitiser. 21 Aerobic glycolysis is the preferred energy metabolism pathway in most cancers 22 including sarcoids, 23 with the extent of reliance on glycolysis generally correlating with tumour malignancy and poorer clinical prognosis. 24 Glycolysis inhibitors rapidly deplete ATP levels and elevate ROS in cancer cells, leading to tumour cell death. 19 Glycolysis inhibition, using drugs such as 2-deoxyglucose and lonidamine, has proved a successful clinical treatment for many human tumours, either as monotherapy or in combination with radiotherapy. [25] [26] [27] In this study, we find that single-treatment ALA PDT, followed by acute topical application of glycolysis inhibitors, dramatically improves the 1-month treatment response rate for equine occult, verrucous, nodular and fibroblastic sarcoids from 14% with ALA PDT only to 93% with ALA PDT followed by 600 μM lonidamine (defined 
| Cell culture
Equine sarcoid cell line EqS04b and primary equine foetal palate fibroblasts EqPalF were gifts of Professor Lubna Nasir (University of Glasgow). 30 Cells were maintained in DMEM, supplemented with 10% horse serum, 100 IU/mL penicillin and 100 μg/mL streptomycin, in a humidified incubator with 5% CO 2 at 37 C.
| Application of PDT in vitro
Cells were seeded at a density of 150,000 cell/well in 24-well plates and allowed to adhere overnight, yielding around 90% confluent monolayers by the following day. Cells were incubated with a lowdose of ALA (21 μg/mL) in serum-free, phenol red-free low-glucose DMEM for 3 hours. For no-photosensitiser control experiments, ALA was not added. Cells were then subjected to PDT (10 J/cm 2 , 32 mW/cm 2 ), using a heat-filtered 500 W white halogen lamp, corre- 
| Skin biopsy studies ex vivo
Full thickness fibroblastic sarcoid tissues were obtained from routine surgical CO 2 laser excisions. Full thickness mouse skin was obtained from the back of euthanized adult C57/BL6 mice and was shaved with a razor blade prior to use. For both types of skin, the epithelial surface was wiped with 70% ethanol and the skin biopsies were cultured on transwell supports in 6-well culture plates over serum-free DMEM, such that the skin sat at an air/medium interface. Biopsies were maintained in a humidified incubator with 5% CO 2 at 37 C.
For ALA uptake studies on live skin, ALA was prepared as either Medicines. ALA in penetration enhancer was soaked into 2 × 2 mm square filter paper, which was then placed onto the skin biopsy.
Creams were thinly applied to the skin in a similar 2 × 2 mm area.
Vehicle-only controls were applied similarly. After incubating for 4 hours, biopsies were fixed in 4% paraformaldehyde, embedded in 20% gelatine and 50 μm transverse sections were cut through the application site using a vibratome. Sections were mounted in Hoechst nuclear stain and viewed with an epifluorescence microscope using ×20 objective.
For studies of glycolysis inhibitor penetration into live sarcoid skin, 300 μM lonidamine or 180 mM 2-deoxy-D-glucose in penetration enhancer were applied onto 2 × 2 mm filter paper squares, placed onto the skin, and incubated for 2 hours. Then the skin surface was rinsed and the biopsy was cut transversely through the application site with a scalpel blade. The 2 halves were placed into serum-free DMEM containing 335 μg/mL ALA and incubated for 1.5 hours. The skin was then rinsed, fixed in 4% paraformaldehyde, gelatin embedded and vibratome-sectioned parallel with the transverse surface that had been exposed to ALA. Sections were mounted in Hoechst nuclear stain and viewed with an epifluorescence microscope using ×20 objective.
| Clinical study design
The study protocol was approved by The Open University Animal 
| Application of PDT in vivo
All procedures were performed on standing horses. Sarcoid skin was cleaned and de-greased with an alcohol wipe. ALA (256 mg/mL in penetration enhancer) was applied to the sarcoid, plus a~5 mm margin, using a cotton bud every 30 minutes for 3 hours (6 applications in total). Horses were maintained away from strong lighting during this time and for 24 hours following PDT. Prior to PDT the horse was sedated, usually intravenously with a combination of detomidine 0.01 mg/kg (Medesedan, Virbac) and butorphanol 0.02 mg/kg (Torbugesic, Zoetis), and the area anaesthetized by a local nerve block, topical Lidocaine gel or topical spray, depending on the site to be treated. Immediately after PDT, glycolysis inhibitor drugs were reconstituted with penetration enhancer solution and mixed well. Glycolysis inhibitors were applied to the sarcoid with a cotton bud every 30 minutes for 2 hours, and then every 2 hours for a further 10 hours (10 applications in total).
For treatment with Metvix, sarcoids were cleaned with an alcohol wipe and a thin layer of Metvix cream was applied for 3 hours.
PDT was delivered as described above for ALA treatments. However, unlike the ALA treatments, Metvix PDT was delivered in 2 sessions, 6-10 days apart.
| Evaluation of treatment outcomes
One month after PDT, the sarcoid size was re-measured with vernier calipers and treatment response was evaluated according to RECIST guidelines. 28 3 | RESULTS
| In vitro cytotoxicity studies
Initially, we investigated whether PDT followed by glycolysis inhibition was more effective than PDT-only at killing equine sarcoid cells in vitro, and whether there was any selectivity for sarcoid cells over normal equine fibroblasts. Because PDT is often administered as several consecutive treatments in vivo, we wanted to understand whether repeated rounds of PDT followed by glycolysis inhibition led to the development of PDT resistance in vitro. Contrary to our expectation, after 4 sequential rounds of PDT then glycolysis inhibition sarcoid cells were further sensitized to PDT (SO4B PDT death: 56.7 AE 9.0% with 2DG; 77.5 AE 5.3%
with Lon) (Figure 1 ). These results suggest that PDT then glycolysis inhibition in vivo could become more effective with each successive round of PDT. However, for the clinical part of this study, ethical approval only permitted 1 ALA PDT treatment per horse.
| PpIX accumulation in sarcoid skin
To translate the in vitro work with glycolysis inhibitors to a clinical setting, we initially examined the accumulation of ppIX fluorescence in ex vivo sarcoid skin, following 4 hours topical application of ALA in a number of formulations to identify the most effective one for subsequent clinical in vivo use. These formulations included: a commercial cream preparation (Mandeville Medicines), 8 
a preparation in
Cetraben emollient cream, and a liquid preparation in a penetration enhancer solution. 29 Then, transverse sections of sarcoid skin were examined using fluorescence microscopy. In every case, including the control treated with penetration enhancer only, we found a high red fluorescence background within the dermis (Figure 2) , possibly due to endogenous porphyrins. 32 However, only in sarcoid skin treated with ALA in penetration enhancer was red fluorescence detected in the epidermis (asterisk in Figure 2D ), implying that this vehicle was the best at delivering ALA into the skin.
To verify these findings, we repeated the ex vivo topical application experiment using normal mouse skin, which we find to have a much lower red fluorescence background. It now became apparent that the penetration enhancer preparation ( Figure 3A ) delivered much more ALA into the superficial epidermis and hair bulbs than the Cetraben cream formulation ( Figure 3B ) and for this reason penetration enhancer solution was selected for all subsequent work.
| Transdermal penetration of glycolysis inhibitors in sarcoid skin
It is technically difficult to measure the skin depth distribution of the glycolysis inhibitors using direct detection methods. However, lonidamine and 2DG both inhibit the metabolism of ALA into ppIX. 21 We took advantage of this effect to indirectly assess the ex vivo skin Figure 4C ). These results indicate that the glycolysis inhibitors fully penetrate the epidermis (about 200-μm thick).
| Clinical data
Based on these encouraging ex vivo tests, we used topical application of ALA in penetration enhancer, with or without post-PDT glycolysis ). In each study arm, treatment response was defined as a sarcoid that demonstrated either CR or PR, whilst treatment failure was defined as a sarcoid that showed either SD or PD. 28 The data are summarized in Tables 1 and 2 and the complete   dataset is presented in Table S1 , Supporting Information. A representative series of photographs of 1 horse, treated with ALA PDT then 600 μM lonidamine, are presented in Figure 6 .
ALA-only PDT mainly resulted in a stabilization of sarcoid growth progression (SD) after 1 month (4/7 cases) or PD (2/7 cases) with 1 case showing a PR. ALA-only PDT demonstrated a non-significant increase in mean sarcoid volume of 13.1 AE 17.9% (AESEM; P > .9999, n = 7). By contrast, ALA PDT followed by either 600 μM lonidamine or Metvix PDT gave significantly greater treatment responses than ALA-only PDT: P = .0001 (ALA-Lon, 25/27) and P = .0047 (Metvix, 7/7). ALA PDT followed by 180 mM 2DG gave a treatment response that was only just non-significant (P = .0573; 9/4) compared with ALA-only PDT. The mean sarcoid volume also significantly decreased 1 month after these treatments, by 80.6 AE 6.8% P < .0001 (ALALon), 66.0 AE 12.9% P = .0039 (ALA-2DG), and 99.0 AE 0.5% P = .0156 (Metvix).
ALA PDT followed by 600 μM lonidamine gave treatment responses that were indistinguishable from those of Metvix PDT (P = 1.0000), and sarcoid volume decreases that were also indistinguishable from those of Metvix PDT (P = .6742). This result is particularly important, because Metvix is applied as 2 separate PDT treatments about 1 week apart, whilst ALA PDT followed by 600 μM lonidamine was applied as a single treatment. Like-for-like comparison of ALA and Metvix treatments was not possible, because single-treatment Metvix PDT was not ethically approved for this study. Similarly, glycolysis inhibitor-only controls were not ethically approved.
| DISCUSSION
We have demonstrated that a combination treatment of ALA PDT followed by glycolysis inhibition selectively kills sarcoid cells in vitro.
Our work further demonstrates that a single application of ALA PDT then glycolysis inhibition can successfully treat most equine occult, PDT than Metvix PDT. 33 However, improvements in the skin penetration of ALA and other photosensitisers will eventually reach a limit, after which the only way to further improve PDT will be by combination therapies, such as glycolysis inhibition, and this area requires further research.
To facilitate adoption of this new PDT technique in clinical practice, subsequent work will need to determine whether our treatment protocol can be simplified. Furthermore, in order to make meaningful comparisons with the current 2-treatment Metvix PDT protocol, treatment response rates need to be examined using a similar 2-treatment regimen for ALA PDT followed by lonidamine. Indeed, our in vitro data indicate that repeated rounds of ALA PDT followed by lonidamine should sensitize any remaining sarcoid cells to subsequent PDT. This 2-treatment protocol is currently being evaluated at the Cambridge equine hospital.
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